ibuprofen alkaloid-int 20 mg/ml peroralna suspenzija
alkaloid - int d.o.o. - ibuprofen - peroralna suspenzija - ibuprofen 20 mg / 1 ml - ibuprofen
lekadol combo 500 mg/ 12,2 mg prašek za peroralno raztopino
lek d.d. - fenilefrin; paracetamol - prašek za peroralno raztopino - fenilefrin 10 mg / 1 vrečica paracetamol500 mg / 1 vrečica; paracetamol 500 mg / 1 vrečica - paracetamol, kombinacije brez psiholeptikov
vesicare 1 mg/ml peroralna suspenzija
astellas pharma d.o.o. - solifenacin - peroralna suspenzija - solifenacin 0,75 mg / 1 ml - solifenacin
ibuprofen nutra essential 100 mg peroralna suspenzija v vrečici
ibuprofen - peroralna suspenzija - ibuprofen 100 mg / 5 ml - ibuprofen
ibuprofen nutra essential 200 mg peroralna suspenzija v vrečici
ibuprofen - peroralna suspenzija - ibuprofen 200 mg / 10 ml - ibuprofen
ibuprofen nutra essential 200 mg peroralna suspenzija v vrečici
ibuprofen - peroralna suspenzija - ibuprofen 200 mg / 10 ml - ibuprofen
ibuprofen nutra essential 400 mg peroralna suspenzija v vrečici
ibuprofen - peroralna suspenzija - ibuprofen 400 mg / 10 ml - ibuprofen
ibuprofen inn-farm 20 mg/ml peroralna suspenzija
ibuprofen - peroralna suspenzija - ibuprofen 20 mg / 1 ml - ibuprofen
ibuprofen nutra essential 400 mg peroralna suspenzija v vrečici
ibuprofen - peroralna suspenzija - ibuprofen 400 mg / 10 ml - ibuprofen
blincyto
amgen europe b.v. - blinatumomab - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.